US FDA accepts Genentech Actemra ’s sBLA for Giant Cell Arteritis

The US Food and Drug Administration (FDA) has accepted Genentech ’s supplemental biologics licence application (sBLA) for Actemra (tocilizumab) for the treatment of Giant Cell Arteritis (GCA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news